Home | Welcome to Contract Pharma   
Last Updated Friday, November 28 2014
Print

Financial Report: Johnson & Johnson 1Q



Published April 16, 2014
Related Searches: Capsules
Johnson & Johnson

1Q Revenues: $18.1 billion (+4%)

1Q Earnings: $4.7 billion (+35%)

Comments: Worldwide pharmaceutical sales were $7.5 billion, up 11%, driven by STELARA, INVEGA, SUSTENNA/XEPLION, PREZISTA, and VELCADE, as well as new products OLYSIO/SOVRIAD, a combination treatment of chronic hepatitis C, and ZYTIGA for the treatment of prostate cancer. Results were negatively impacted by loss of exclusivity for ACIPHEX and CONCERTA. In the quarter, the FDA approved IMBRUVICA capsules for the treatment of chronic lymphocytic leukemia, and the European Commission granted conditional approval for SIRTURO as part of a combination regimen for pulmonary multi-drug resistant tuberculosis. R&D expenses were $1.8 billion, up 3%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On